Stichting MelanomaSarcomaGroningana

Publicaties

Sloot S, Fedorenko IV, Smalley KS, Gibney GT. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? Expert Opin Pharmacother. 2014 Apr;15(5):589-92.

Bosscher MR, van Leeuwen BL, Hoekstra HJ. Surgical emergencies in oncology. Cancer Treat Rev. 2014 Sep;40(8):1028-36.

Sloot S, Rashid OM, Zager JS. Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1355-64

Sloot S, Rashid OM, Zager JS. Intralesional therapy for metastatic melanoma. Expert Opin Pharmacother. 2014 Dec;15(18):2629-39.

Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar;5(3):264-73

Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol. 2015 Mar;122(1):121-6

Speijers MJ, Bastiaannet E, Sloot S, Suurmeijer AJ, Hoekstra HJ. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015 Sep;22(9):2978-87.

Holtkamp LH, Wang S, Wilmott JS, Madore J, Vilain R, Thompson JF, Nieweg OE, Scolyer RA. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases. Ann Surg Oncol. 2015 Sep;22(9):2972-7

Bosscher MR, Bastiaannet E, van Leeuwen BL, Hoekstra HJ Current management of surgical oncologic emergencies. PLoS One. 2015;10(5):e0124641.

Speijers MJ, Bastiaannet E, Sloot S, Suurmeijer AJ, Hoekstra HJ.Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. Ann Surg Oncol. 2015;22(9):2978-87.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016 Feb;26(1):83-7.

Bosscher MR, Bastiaannet E, van Leeuwen BL, Hoekstra HJ. Factors Associated with Short-Term Mortality After Surgical Oncologic Emergencies. Ann Surg Oncol. 2016;23(6):1803-14

Damude S, Hoekstra HJ, Bastiaannet E, Muller Kobold AC, Kruijff S, Wevers KP. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Eur J Surg Oncol. 2016;42(4):545-51.

Damude S, Niebling MG, Kobold AC, Hoekstra HJ, Kruijff S, Wevers KP. Adipocytes in venipunctures cause falsely elevated S-100B serum values. Clin Chem Lab Med. 2016;54(8):e235-7.

Sloot S, Speijers MJ, Bastiaannet E, Hoekstra HJ. Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature.Cancer Treat Rev. 2016; 45:120-8.

Damude S, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO-Study: Prospective, Randomized, Clinical Trial for the Evaluation of a Stage-adjusted Reduced Follow-up Schedule in Cutaneous Melanoma Patients-Results after 1 Year. Ann Surg Oncol. 2016;23(9):2762-71

Slump J, Ferguson PC, Wunder JS, Griffin A, Hoekstra HJ, Bagher S, Zhong T, Hofer SO, O’Neill AC. Can the ACS-NSQIP surgical risk calculator predict post-operative complications in patients undergoing flap reconstruction following soft tissue sarcoma resection? J Surg Oncol. 2016;114(5):570-575.

Sloot S,, Rashid OM, Sarnaik AA, Zager JS. Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control. 2016; 23(1):12-20. Review.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016;26(1):83-7.

Holtkamp LHJ, Read RL, Emmett L, Thompson JF, Nieweg OE. Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Res. 2017t;27(5):457-462.

Stevenson MG, Musters AH, Geertzen JHB, van Leeuwen BL, Hoekstra HJ, Been LB. Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: Local control and survival. J Surg Oncol. 2017 Oct 16. doi: 10.1002/jso.24881. [Epub ahead of print]

Verstijnen J, Damude S, Hoekstra HJ, Kruijff S, Ten Tije AJ, Louwman WJ, Bastiaannet E, Stuiver MM. Practice variation in Sentinel Lymph Node Biopsy for melanoma patients in different geographical regions in the Netherlands. Surg Oncol. 2017; 26:431-437.

 

 

Proefschriften

M.R.F. Bosscher. Surgical Oncologic Emergencies. Decision Making and Clinical Outcome. RUG 21-09-2015

S. Sloot. Developments in the treatment of advanced melanoma. RUG 22-11-2017